Maintenance therapy after first‐line therapy for ovarian cancer: Quantitative effectiveness
S
Susana M. Campos
(Gynecology Oncology, Department of Obstetrics and Gynecology Dana‐Farber Cancer Institute Boston Massachusetts USA)
J
Jessica DiSilvestro
(Gynecology Oncology, Department of Obstetrics and Gynecology Tufts Medical Center Boston Massachusetts USA)
S
Stephanie V. Blank
(Gynecology Oncology, Department of Obstetrics Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai New York New York USA)
Article Details
Volume / Issue
Vol. 76, Issue 1
Published
January 01, 2026
ISSN
0007-9235
Publisher
Wiley
Authors (3)
S
Susana M. Campos
Gynecology Oncology, Department of Obstetrics and Gynecology Dana‐Farber Cancer Institute Boston Massachusetts USA
J
Jessica DiSilvestro
Gynecology Oncology, Department of Obstetrics and Gynecology Tufts Medical Center Boston Massachusetts USA
S
Stephanie V. Blank
Gynecology Oncology, Department of Obstetrics Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai New York New York USA
Related Articles from this Journal
Systemic amyloid light‐chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates
Xia Wu, Heather Landau et al.
May 2026
10.3322/caac.70092
Screening for colorectal cancer
May 2026
10.3322/caac.70087
Correction to “Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases”
May 2026
10.3322/caac.70093
Blood tests for colorectal cancer—Hype ahead of evidence?
Gloria D. Coronado, David A. Lieberman
May 2026
10.3322/caac.70088
Medullary thyroid carcinoma and <i>RET</i> molecular testing: A virtual tumor board on clinical decision‐making
Lucas Kallas‐Silva, Victor Alexandre dos Santos Valsecchi et al.
May 2026
10.3322/caac.70086